STI-6129

BIOLOGICAL5 trials

Sponsors

Sorrento Therapeutics, Inc., Zhejiang ACEA Pharmaceutical Co. Ltd.

Conditions

Advanced Solid TumorLight Chain (AL) AmyloidosisMultiple MyelomaRelapsed or Refractory Multiple Myeloma

Phase 1

Study of the Safety and Efficacy of STI-6129 in Patients With Relapsed or Refractory Systemic AL Amyloidosis

Sorrento Therapeutics, Inc.Light Chain (AL) Amyloidosis

Start: 2021-04-01End: 2024-12-31Target: 60Updated: 2023-01-17

Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma

Active, not recruitingNCT05308225

Sorrento Therapeutics, Inc.Multiple Myeloma

Start: 2023-02-01End: 2026-07-31Updated: 2023-04-12

Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma

RecruitingNCT05565807

Zhejiang ACEA Pharmaceutical Co. Ltd.Relapsed or Refractory Multiple Myeloma

Start: 2023-02-09End: 2028-02-19Target: 84Updated: 2025-08-15

Study to Access Anti-CD38 Anibody Drug in Patients With Advanced Solid Tumors

Sorrento Therapeutics, Inc.Advanced Solid Tumor

Start: 2023-03-31End: 2025-10-31Target: 34Updated: 2023-01-30

An Open-Label Study of the Safety of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With AL Amyloidosis

WithdrawnNCT05692908

Sorrento Therapeutics, Inc.Light Chain (AL) Amyloidosis

Start: 2023-09-30End: 2024-11-30Updated: 2023-04-28